Advertisement

TRVN

Trevena, Inc.

Healthcare · USD

Set alert

Price alert · TRVN

All alert types
0.01 USD 0.00 0.00%
As of Oct 29, 2026
0.012 Day range 0.012
0.0003 52-week range 0.066
YTD
-7.50%
1 year
-7.50%
Open
0.012
Prev close
0.0111
Mkt cap
9.59K
Vol
210
Avg vol
212
EPS
-290.10
P/E
0.00
Div yield
0.00%
More statistics
Low
0.012
High
0.012
Forward P/E
-0.09
Beta
0.00
Short ratio
1.00
Inst. own
10.50%
Dividend
0.00
Ex-div date
50-d avg
3.32
200-d avg
8.10
1y target
100.00

2Y chart

Chart tools
Interval
TRVN two-year price chart0.000.591.181.762.35Oct 24Mar 25Aug 25Jan 26Jun 26Oct 26

Key statistics

Market cap
1.60M
Enterprise value
0
Trailing P/E
0.00
Forward P/E
-0.09
PEG ratio
0.00
Price / sales
0.00
Price / book
0.00
EPS (TTM)
-56.50
Beta
0.00
Dividend yield
0.00%
Payout ratio
0.00%
Profit margin
0.00%
Revenue (TTM)
0
Revenue growth
0.00%
Free cash flow
0
Total cash
0
Total debt
0
Return on equity
0.00%
Shares outstanding
852.93K
Short % of float
7.03%
50-day average
3.32
200-day average
8.10

Analyst view

Consensus: buy

Buy
Price target (mean) 100.00 +900800.9% upside
Target (low)
75.00
Target (mean)
100.00
Target (high)
125.00
Ratings (0m) 8 7 buy · 1 hold · 0 sell
  • Strong buy2
  • Buy5
  • Hold1
  • Sell0
  • Strong sell0

Next earnings

Consensus EPS estimate -7.37.

Earnings history

Financials — quick view

All financials
TRVN Revenue — quarterly 325.00K
2020-Q3 20202020-Q4 20202021-Q1 20212021-Q2 20212021-Q3 20212021-Q4 20212022-Q1 20222022-Q2 20222022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 2024
TRVN Net income — quarterly -4.89M
2020-Q3 20202020-Q4 20202021-Q1 20212021-Q2 20212021-Q3 20212021-Q4 20212022-Q1 20222022-Q2 20222022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 2024
TRVN EPS — quarterly -5.75
2020-Q3 20202020-Q4 20202021-Q1 20212021-Q2 20212021-Q3 20212021-Q4 20212022-Q1 20222022-Q2 20222022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 2024

Earnings

TRVN recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Nov 7, 2024Sep 1, 20240.00-5.79——
Aug 8, 2024Jun 1, 2024-9.25-5.75+3.50+37.84%
May 15, 2024Mar 1, 2024-9.25-9.00+0.25+2.70%
Apr 1, 2024Dec 1, 2023-13.00-26.50-13.50-103.85%
Nov 14, 2023Sep 1, 20230.00-14.25——
Aug 14, 2023Jun 1, 2023-11.25-17.25-6.00-53.33%

Upgrades / downgrades

TRVN analyst upgrades and downgrades
DateFirmActionFromTo
May 16, 2023JMP SecuritiesreitMarket OutperformMarket Outperform
Mar 30, 2023HC Wainwright & Co.reit—Buy
Mar 30, 2023JMP Securitiesreit—Market Outperform

About Trevena, Inc.

Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV734, a small molecule G protein biased ligand of the MOR, which has completed phase I studies for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain. Trevena, Inc. was incorporated in 2007 and is headquartered in Chesterbrook, Pennsylvania.

Sector
Healthcare
Industry
Biotechnology
Country
United States
Website
trevena.com

News

Your note

Sign in to keep a note on TRVN — it syncs with the Stock Master app.

Insider holders

TRVN insider holders
InsiderRelationLatest transactionDateShares held
BOURDOW CARRIE LChief Executive OfficerStock Award(Grant)Dec 13, 2023642,923
DEMITRACK MARK AOfficerStock Award(Grant)Dec 13, 2023306,224
DRAKE PATRICIA MOfficerStock Award(Grant)Dec 13, 2023107,078
SHIN BARRYChief Financial OfficerStock Award(Grant)Dec 13, 2023308,821
YODER ROBERT T.OfficerStock Award(Grant)Dec 13, 2023158,877

Institution ownership

TRVN institution ownership
Holder% heldSharesValueReported
Renaissance Technologies, LLC1.33%182,152160.47KJun 29, 2023
Blackrock Inc.0.82%112,17398.82KJun 29, 2023
Vanguard Group Inc0.53%72,81264.15KJun 29, 2023
Geode Capital Management, LLC0.48%65,16757.41KJun 29, 2023
Simplex Trading, LLC0.27%37,59033.12KJun 29, 2023
Captrust Financial Advisors0.24%33,07629.14KJun 29, 2023

Fund ownership

TRVN fund ownership
Holder% heldSharesValueReported
Vanguard Extended Market Index Fund0.51%70,17661.83KJun 29, 2023
Fidelity Extended Market Index Fund0.24%33,09537.73KMay 30, 2023
Fidelity OTC Portfolio0.13%17,80615.49KAug 30, 2023
Fidelity Total Market Index Fund0.07%8,94610.20KMay 30, 2023
Fidelity NASDAQ Composite Index Fund0.05%7,4578.50KMay 30, 2023
Fidelity Series Total Market Index Fund0.05%7,3588.39KMay 30, 2023
Advertisement